ABD - İngilizce - NLM (National Library of Medicine)

waylis therapeutics llc - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - aciphex delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd). for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of aciphex may be considered. aciphex delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance). controlled studies do not extend beyond 12 months. aciphex delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks. aciphex delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. most patients heal within four weeks. aciphex delayed-release tablets, in combination with amoxicillin and clarithromycin as a

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: mannitol; magnesium stearate; diethyl phthalate; ethylcellulose; hypromellose phthalate; purified talc; iron oxide yellow; light magnesium oxide; povidone; sodium starch glycollate type a; titanium dioxide - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: light magnesium oxide; purified talc; diethyl phthalate; povidone; hypromellose phthalate; titanium dioxide; magnesium stearate; mannitol; sodium starch glycollate type a; ethylcellulose; iron oxide red - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: sodium stearylfumarate; purified talc; hyprolose; hypromellose; iron oxide yellow; mannitol; iron oxide red; dibutyl sebacate; hypromellose phthalate; titanium dioxide; calcium hydroxide - rabeprazole sandoz is indicated for treatment and prevention of relapse of gastro-oesophageal reflux disease; symptomatic treatment of gastro-oesophageal reflux disease; treatment of duodenal ulcers; treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole sandoz is also indicated, in combination with clarithromycin and amoxycillin, for eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis; and healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide yellow; sodium stearylfumarate; hypromellose phthalate; calcium hydroxide; hypromellose; purified talc; titanium dioxide; dibutyl sebacate; hyprolose; mannitol - rabeprazole sandoz is indicated for treatment and prevention of relapse of gastro-oesophageal reflux disease; symptomatic treatment of gastro-oesophageal reflux disease; treatment of duodenal ulcers; treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole sandoz is also indicated, in combination with clarithromycin and amoxycillin, for eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis; and healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: heavy magnesium oxide; diacetylated monoglycerides; mannitol; iron oxide yellow; hypromellose phthalate; titanium dioxide; light magnesium oxide; purified talc; magnesium stearate; ethylcellulose; hyprolose; propylene glycol; butan-1-ol; allura red ac aluminium lake; industrial methylated spirit; ethanol; shellac; strong ammonia solution; sulfuric acid - treatment and prevention of relapse of gastro-oesophageal reflux disease. symptomatic treatment of gastro-oesophageal reflux disease. treatment of duodenal ulcers. treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

ABD - İngilizce - NLM (National Library of Medicine)

rebel distributors corp - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - warfarin sodium tablets are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. warfarin sodium tablets are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. warfarin sodium tablets are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. anticoagulation is contraindicated in any localized or general physical condition or personal circumstance in which the hazard of hemorrhage might be greater than the potential clinical benefits of anticoagulation, such as: warfarin sodium tablets are contraindicated in women who are or may become pregnant because the drug passes through the placental barrier and may cause fatal hemorrhage to the fetus in utero. furthermore, there have been reports of birth malformations in children born to mothers who

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rabeprazole sodium -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - rabeprazole sodium -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rabeprazole sodium -